This website contains promotional content and is intended for Healthcare Professionals based in the United States only.
This article offers a practical, evidence-based overview of FVIII infusion, dosing, administration, and the management of key clinical challenges, including inhibitor development and strategies that support individualized, patient-centered care.
Hemophilia is an inherited bleeding disorder caused by a deficiency of either clotting factor VIII (hemophilia A) or IX (hemophilia B), leading to impaired blood clotting and an increased risk of prolonged or spontaneous bleeding. Clotting factor therapy, which involves intravenous administration of factor VIII or IX, restores the clotting and remains a cornerstone of hemophilia management.1,2 While other treatments are available, this article focuses specifically on clotting factor replacement delivered through intravenous infusion.
Hemophilia A is a bleeding disorder caused by Factor VIII (FVIII) deficiency, with severity linked to FVIII activity levels. This article explores FVIII biology, defines activity ranges, and reviews current approaches to replacement therapy.
Pharmacokinetic (PK) testing with accurate Factor VIII assays may help personalize hemophilia A treatment.1,2 This article reviews one-stage and chromogenic methods and their clinical use.
Factor VIII (FVIII) replacement therapies have been a step forward for the prevention and treatment of bleeding episodes in patients with hemophilia A. One remaining challenge is the development of neutralizing antibodies, known as inhibitors, which interfere with patient response to a factor infusion or render it ineffective.
Hemophilia A–a rare bleeding disorder–often goes undiagnosed in women because of the misconception that it only affects men, due to its X-linked recessive inheritance pattern. Although factor levels above 50% are usually considered within the normal range, emerging data suggest that some women and girls with levels between 50% and 60% may still have an increased risk of bleeding symptoms. Additionally, they may have sex-specific symptoms such as heavy menstrual bleeding and postpartum hemorrhage. This highlights the need for a more nuanced understanding of hemophilia A as it pertains to women.
MAT-US-2500602-v3.0-04/2026
